1835 Results for "

Injury

" in MedChemExpress (MCE) Product Catalog:

Products (1835)

Sort by :

Categories

By Targets

Species:

Tags:

Sources:

Hosts:

Reactivities:

Applications:

Isotypes:

Conjugations:

Clonalities:

Modifications:

Products

669

ML385

669 Publications Verification

Cat. No.: HY-100523

CAS No.: 846557-71-9

Purity: 99.96%

Target:

Keap1-Nrf2 Ferroptosis Apoptosis mTOR

Research Areas:

Cardiovascular Disease Cancer

ML385 is a potent and selective Nrf2 inhibitor with an IC₅₀ of 1.9 μM. ML385 directly binds to the Neh1 domain of NRF2, interferes with the binding of the MAFG-NRF2 protein complex to the antioxidant response element (ARE) DNA sequence, thereby blocking the expression of downstream target genes of NRF2. ML385 can be used in studies related to adult T-cell leukemia, breast cancer, myocardial ischemia/reperfusion injury, non-small cell lung cancer, esophageal squamous cell carcinoma, head and neck squamous cell carcinoma, and lung squamous cell carcinoma .

Compare

Please select quantity

August 31

Get Quote

View All Sizes

223

Metformin hydrochloride

223 Cited Publications

Cat. No.: HY-17471A

CAS No.: 1115-70-4

Synonyms: 1,1-Dimethylbiguanide hydrochloride

Target:

AMPK Autophagy Mitophagy Apoptosis mTOR

Research Areas:

Cardiovascular Disease Infection Neurological Disease Metabolic Disease Inflammation/Immunology Cancer

Metformin (1,1-Dimethylbiguanide) hydrochloride inhibits the mitochondrial respiratory chain in the liver, leading to AMPK activation and enhancing insulin sensitivity, and can be used in the study of type 2 diabetes. Metformin hydrochloride exerts central glucose-lowering effects by inhibiting Ras-related protein 1 (Rap1) in SF1 hypothalamic neurons. Metformin hydrochloride also inhibits liver oxidative stress, nitrosative stress, inflammation, and apoptosis caused by liver ischemia/reperfusion injury. In addition, Metformin hydrochloride regulates the expression of autophagy-related proteins by activating AMPK and inhibiting the mTOR signaling pathway, thereby inducing tumor cell autophagy and inhibiting the growth of renal cell carcinoma in vitro and in vivo .

Compare

Please select quantity

August 31

Get Quote

View All Sizes

223

Metformin

223 Cited Publications

Cat. No.: HY-B0627

CAS No.: 657-24-9

Synonyms: 1,1-Dimethylbiguanide

Target:

AMPK Autophagy Mitophagy Apoptosis mTOR

Research Areas:

Cardiovascular Disease Infection Neurological Disease Metabolic Disease Inflammation/Immunology Cancer

Metformin (1,1-Dimethylbiguanide) inhibits the mitochondrial respiratory chain in the liver, leading to AMPK activation and enhancing insulin sensitivity, and can be used in the study of type 2 diabetes. Metformin exerts central glucose-lowering effects by inhibiting Ras-related protein 1 (Rap1) in SF1 hypothalamic neurons. Metformin also inhibits liver oxidative stress, nitrosative stress, inflammation, and apoptosis caused by liver ischemia/reperfusion injury. In addition, Metformin regulates the expression of autophagy-related proteins by activating AMPK and inhibiting the mTOR signaling pathway, thereby inducing tumor cell autophagy and inhibiting the growth of renal cell carcinoma in vitro and in vivo .

Compare

Please select quantity

August 31

Get Quote

View All Sizes

200

MitoTEMPO hydrate

200 Cited Publications

Cat. No.: HY-125944

CAS No.: 1569257-94-8

Purity: 98.03%

Target:

Mitochondrial Metabolism PINK1/Parkin NOD-like Receptor (NLR) Autophagy Calcium Channel Apoptosis

Research Areas:

Cardiovascular Disease Neurological Disease Metabolic Disease Endocrinology

MitoTEMPO hydrate is a mitochondria-targeted antioxidant . MitoTEMPO hydrate induces mitophagy by activating the PINK1/Parkin pathway, inhibits NLRP3 inflammasome activation, restores mitochondrial membrane potential, and improves renal function and podocyte injury. MitoTEMPO hydrate regulates Ca ²⁺ homeostasis, inhibits Bnip3 overexpression, shortens action potential duration, and exerts antiarrhythmic effects. MitoTEMPO hydrate reverses premature senescence, reduces trabecular bone loss, and decreases cell apoptosis. MitoTEMPO hydrate can be used in studies of chronic kidney disease, age-related cardiac dysfunction, postmenopausal osteoporosis, and ischemic stroke .

Compare

Please select quantity

August 31

Get Quote

View All Sizes

200

Mito-TEMPO

200 Cited Publications

Cat. No.: HY-112879

CAS No.: 1334850-99-5

Purity: 99.19%

Target:

Calcium Channel PINK1/Parkin Mitochondrial Metabolism Apoptosis Autophagy NOD-like Receptor (NLR)

Research Areas:

Cardiovascular Disease Neurological Disease Metabolic Disease Inflammation/Immunology

Mito-TEMPO is a mitochondria-targeted antioxidant. Mito-TEMPO induces mitophagy by activating the PINK1/Parkin pathway, inhibits NLRP3 inflammasome activation, restores mitochondrial membrane potential, and improves renal function and podocyte injury. Mito-TEMPO regulates Ca ²⁺ homeostasis, inhibits Bnip3 overexpression, shortens action potential duration, and exerts antiarrhythmic effects. Mito-TEMPO reverses premature senescence, reduces trabecular bone loss, and decreases cell apoptosis. Mito-TEMPO can be used in studies of chronic kidney disease, age-related cardiac dysfunction, postmenopausal osteoporosis, and ischemic stroke .

Compare

Please select quantity

August 31

Get Quote

View All Sizes

183

Docetaxel

183 Cited Publications

Cat. No.: HY-B0011

CAS No.: 114977-28-5

Synonyms: RP-56976

Category:

Terpenoids Diterpenoids Endogenous metabolite Disease Research Fields Cancer

Target:

Microtubule/Tubulin Cytochrome P450 Apoptosis Drug Derivative

Docetaxel (RP-56976) is an orally active tubulin stabilizer with antitumor activity. Docetaxel is a P-glycoprotein substrate and is metabolized by CYP3A to inactive products. Docetaxel binds tubulin, promotes tubulin polymerization, and inhibits microtubule depolymerization. Docetaxel induces aberrant mitosis followed by necrotic-like cell death at low concentrations, and induces G2/M mitotic arrest and drives apoptosis at high concentrations. Docetaxel induces renal injury/renal alterations, sex-dependent granule toxicity/uptake, low cardiac delivery, and decreased hepatic SOD/increased catalase/hepatotoxicity. Docetaxel can be used in cancer-related research .

Compare

Please select quantity

August 31

Get Quote

View All Sizes

183

Docetaxel Trihydrate

183 Cited Publications

Cat. No.: HY-B0011A

CAS No.: 148408-66-6

Synonyms: RP-56976 Trihydrate

Target:

Microtubule/Tubulin Cytochrome P450 Apoptosis Drug Derivative

Research Areas:

Cancer

Docetaxel Trihydrate (RP-56976 Trihydrate) is an orally active tubulin stabilizer with antitumor activity. Docetaxel Trihydrate is a P-glycoprotein substrate and is metabolized by CYP3A to inactive products. Docetaxel Trihydrate binds tubulin, promotes tubulin polymerization, and inhibits microtubule depolymerization. Docetaxel Trihydrate induces aberrant mitosis followed by necrotic-like cell death at low concentrations, and induces G2/M mitotic arrest and drives apoptosis at high concentrations. Docetaxel Trihydrate induces renal injury/renal alterations, sex-dependent granule toxicity/uptake, low cardiac delivery, and decreased hepatic SOD/increased catalase/hepatotoxicity. Docetaxel Trihydrate can be used in cancer-related research .

Compare

Please select quantity

August 31

Get Quote

View All Sizes

179

Resveratrol

179 Cited Publications

Cat. No.: HY-16561

CAS No.: 501-36-0

Synonyms: trans-Resveratrol; SRT501

Category:

Anti-aging 500 - Internal Server Error | MedChemExpress

country

Change Language

EN - English
FR - Français
DE - Deutsch
ES - Español
JA - 日本語
KO - 한국어

Country or Region:

United States

Cart

Product Name	Size / Unit Price	Qty

Total: USD 0.00 Checkout

Oops!

Sorry, Something went wrong on our server.
Our team has been notified and is working to fix the issue.